This triplet combination is safe and effective in patients with relapsed/refractory multiple myeloma... CART-ddBCMA demonstrated a 100% overall response rate in patients with relapsed/refractory multiple myeloma. Patients with both multiple myeloma (MM) and secondary immunodeficiencies (SID) face... Adding a monoclonal antibody to a triplet treatment significantly lowered the risk of disease... The data were from the phase III DETERMINATION trial... Adding ixazomib to pomalidomide and dexamethasone improved progression-free survival rates... The number of "chemotherapy-free" drugs and regimens grows as more is learned about the biology of hematologic malignancies. The European Commission (EC) has granted marketing authorization for selinexor, an oral exportin 1 inhibitor... The EMA’s CHMP recommendation is based on positive results from the multicohort, open-label... The benefit of maintenance therapy with ixazomib after allogenic hematopoietic stem cell transplantation... In patients with newly diagnosed MM, the addition of AHSCT to a triplet regimen of lenalidomide, bortezomib, and ... The FDA has cleared the IND application for LAVA-051, humanized Gammabody designed to activate...